Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 11/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.35 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.35 |
| ▸ | ADK | P55263 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630494 | 0.89 | ATG7 (0.45) | ATG7CA2NAE1UBA3 | |
| SCHEMBL18630848 | 0.87 | ATG7 (0.44) | ATG7CA2NAE1UBA3 | |
| SCHEMBL1798206 | 0.84 | ATG7 (0.56) | ATG7CA2 | |
| SCHEMBL12567198 | 0.84 | ATG7 (0.46) | ATG7NAE1UBA3 | |
| SCHEMBL12652426 | 0.83 | ATG7 (0.46) | ATG7CA2NAE1UBA3 | |
| SCHEMBL18630418 | 0.82 | ATG7 (0.40) | ATG7CA2NAE1UBA3 | |
| SCHEMBL1795247 | 0.73 | ATG7 (0.55) | ATG7CA2 | |
| SCHEMBL20938378 | 0.73 | ADK (0.44) | ATG7CA2ADK | |
| SCHEMBL1796949 | 0.72 | ATG7 (0.54) | ATG7CA2 | |
| SCHEMBL12566819 | 0.72 | NPC1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ATG7 2417/4885CA2 4021/4885NAE1 257/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ATG7 2417/4885CA2 4021/4885NAE1 257/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ATG7 1114/4885CA2 3826/4885NAE1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.